Literature DB >> 7373347

Ultrastructural localization of the terminal and lytic ninth complement component (C9) at the motor end-plate in myasthenia gravis.

K Sahashi, A G Engel, E H Lambert, F M Howard.   

Abstract

The terminal and lytic complement component (C9) was localized at the motor end-plate in acquired autoimmune myasthenia gravis (MG) by the immunoperoxidase method, with adequate preservation of fine structure and negligible background staining. C9 was localized on short segments of the postsynaptic membrane on degenerated fragments of the junctional folds shed into the synaptic space, and on disintegrating junctional folds. An inverse relationship was noted between the structural integrity of the junctional folds and the abundance of C9 at a given end-plate region. Destruction of junctional folds by complement may induce relocation of the nerve terminal and increased spatial separation of end-plate regions on the muscle fiber. Destruction of junctional folds by the complement membrane attack complex is a cause of the acetylcholine receptor deficiency at the MG end-plate, but antibody-dependent modulation of the receptor may also contribute to deficiency of the receptor. In certain disorders other than autoimmune MG, pathological mechanisms other than complement-mediated lysis may affect the structural integrity of the postsynaptic region.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7373347     DOI: 10.1097/00005072-198003000-00005

Source DB:  PubMed          Journal:  J Neuropathol Exp Neurol        ISSN: 0022-3069            Impact factor:   3.685


  46 in total

Review 1.  Mechanisms underlying autoimmune synaptic encephalitis leading to disorders of memory, behavior and cognition: insights from molecular, cellular and synaptic studies.

Authors:  Emilia H Moscato; Ankit Jain; Xiaoyu Peng; Ethan G Hughes; Josep Dalmau; Rita J Balice-Gordon
Journal:  Eur J Neurosci       Date:  2010-07-14       Impact factor: 3.386

Review 2.  Immunopathologic events at the endplate in myasthenia gravis.

Authors:  T Ashizawa; S H Appel
Journal:  Springer Semin Immunopathol       Date:  1985

3.  Effect of complement and its regulation on myasthenia gravis pathogenesis.

Authors:  Linda L Kusner; Henry J Kaminski; Jindrich Soltys
Journal:  Expert Rev Clin Immunol       Date:  2008-01       Impact factor: 4.473

Review 4.  Myasthenia gravis: an autoimmune response against the acetylcholine receptor.

Authors:  Y M Graus; M H De Baets
Journal:  Immunol Res       Date:  1993       Impact factor: 2.829

5.  Markedly enhanced susceptibility to experimental autoimmune myasthenia gravis in the absence of decay-accelerating factor protection.

Authors:  Feng Lin; Henry J Kaminski; Bianca M Conti-Fine; Wei Wang; Chelliah Richmonds; M Edward Medof
Journal:  J Clin Invest       Date:  2002-11       Impact factor: 14.808

Review 6.  Therapies Directed Against B-Cells and Downstream Effectors in Generalized Autoimmune Myasthenia Gravis: Current Status.

Authors:  Grayson Beecher; Brendan Nicholas Putko; Amanda Nicole Wagner; Zaeem Azfer Siddiqi
Journal:  Drugs       Date:  2019-03       Impact factor: 9.546

Review 7.  The role of complement in experimental autoimmune myasthenia gravis.

Authors:  Linda L Kusner; Henry J Kaminski
Journal:  Ann N Y Acad Sci       Date:  2012-12       Impact factor: 5.691

8.  Extraocular muscle susceptibility to myasthenia gravis: unique immunological environment?

Authors:  Jindrich Soltys; Bendi Gong; Henry J Kaminski; Yuefang Zhou; Linda L Kusner
Journal:  Ann N Y Acad Sci       Date:  2008       Impact factor: 5.691

9.  Immunolocalization of complement component C9 on necrotic and non-necrotic muscle fibres in myositis using monoclonal antibodies: a primary role of complement in autoimmune cell damage.

Authors:  B P Morgan; C A Sewry; K Siddle; J P Luzio; A K Campbell
Journal:  Immunology       Date:  1984-05       Impact factor: 7.397

10.  A functional SNP in the regulatory region of the decay-accelerating factor gene associates with extraocular muscle pareses in myasthenia gravis.

Authors:  J M Heckmann; H Uwimpuhwe; R Ballo; M Kaur; V B Bajic; S Prince
Journal:  Genes Immun       Date:  2009-08-13       Impact factor: 2.676

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.